Penumbra Inc(PEN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #352 of 2,879 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PEN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Penumbra Inc (PEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PEN at 69.7/100 on a 32-signal composite quality model, placing it at rank #352 of 2,879 stocks — the top 25% of the AI-ranked universe. PEN scores in the top quartile across earnings quality (91.1), balance sheet strength (84.5), profitability (79.5). Areas of concern include institutional flow (28.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Penumbra Inc reports quarterly revenue of $374.8M, net income of $32.6M, an operating margin of 10.2%. Top institutional holders of PEN by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PEN trades on the NYSE exchange and files with the SEC under CIK 1321732. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Penumbra Inc directly from SEC EDGAR. Penumbra Inc's 13F Pro composite quality score has ranged between 8 and 78 since 2021, currently 69.7 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving PEN's Business? Latest 10-Q Breakdown
✓ 28/28 datapoints verifiedAI-extracted from Penumbra Inc's 10-Q filed 2026-05-06 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Penumbra revenue grew 15.6% YoY to $374.8M, driven by thrombectomy (+12.1%) and embolization/access (+23.8%), though operating income declined 5.2% due to $39.3M SG&A increase largely from Boston Scientific acquisition costs.
Biggest Revenue Drivers
Total revenue: $374.8M+15.6% YoY
Higher sales volume in the United States from further market penetration of existing products
Higher sales volume in the United States from further market penetration of new and existing products
Largest Expense Items
$17.2M personnel increase from headcount growth, $9.4M acquisition-related expenses for Boston Scientific deal, $3.1M marketing event costs
Proportional to revenue growth
$1.6M personnel expense increase offset by $1.3M decrease in product development timing
Margins: Gross margin expanded 100 basis points to 67.6% despite revenue growth, primarily driven by favorable product mix across regions. Operating margin compressed to 10.2% from 12.4% due to SG&A deleverage from acquisition-related costs and personnel expansion.
Watch Items from the Filing
- Pending Boston Scientific acquisition at $14.5B enterprise value ($374/share) expected to close by end of 2026; $9.4M acquisition costs incurred Q1 2026, with $525M termination fee owed by Penumbra if deal fails.
- Costa Rica manufacturing facility project cost increased ~$28M in Q1 2026 (total now ~$116M estimated); $42.4M paid to date through March 31, 2026.
- International revenue 20.9% of total; most non-US sales denominated in euros with FX exposure; 10% adverse currency move would not materially impact net income per management.
- Labor settlement of $4.6M fully paid by June 2025; final court approval granted February 2026 for California wage/hour class and PAGA actions.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$374.8M
Net Income
Q1 2026
$32.6M
Free Cash Flow
Q1 2026
$73.3M
Operating Margin
Q1 2026
10.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+17.5% YoYNet Income
+1168.1% YoYOperating Income
+1939.5% YoYEPS (Diluted)
+1155.6% YoYTotal Assets
+19.1% YoYOp. Cash Flow
+41.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.40B +17.5% | $1.19B +12.9% | $1.06B +25.0% | $847.1M +13.3% | $747.6M +33.4% | $560.4M |
| Net Income | $177.7M +1168.1% | $14.0M -84.6% | $91.0M +4643.2% | $-2.0M -137.9% | $5.3M +133.7% | $-15.7M |
| Operating Income | $189.2M +1939.5% | $9.3M -87.4% | $73.6M +1109.3% | $6.1M +181.1% | $-7.5M +80.7% | $-38.9M |
| EPS (Diluted) | $4.52 +1155.6% | $0.36 -84.5% | $2.32 +4740.0% | $-0.05 -135.7% | $0.14 +131.8% | $-0.44 |
| Total Assets | $1.83B +19.1% | $1.53B -1.5% | $1.56B +13.5% | $1.37B +10.2% | $1.24B +51.2% | $823.0M |
| Operating Cash Flow | $238.7M +41.7% | $168.5M +73.1% | $97.3M +274.9% | $-55.7M -685.8% | $9.5M +128.6% | $-33.2M |
AI Insight: PEN Financial Trends
Penumbra delivered strong 25% revenue growth from Q2 2024 to Q1 2026 despite recent sequential softening.
• Revenue grew from $299M in Q2 2024 to $375M in Q1 2026, representing 25% growth over eight quarters.
• Company returned to profitability in Q3 2024 after $60M loss in Q2 2024, sustaining positive earnings through Q1 2026.
• Operating cash flow strengthened significantly from $23M in Q2 2024 to $87M in Q1 2026.
• Equity base expanded steadily from $1,161M in Q2 2024 to $1,474M in Q1 2026 with no debt burden.
⚠ Revenue declined sequentially from $385M in Q4 2025 to $375M in Q1 2026, breaking growth momentum.
⚠ Net income dropped from $47M in Q4 2025 to $33M in Q1 2026 despite higher operating cash flow.
AI Insight: PEN Ratio Trends
Penumbra's profitability metrics declined sharply in Q1 2026, with operating margin falling to 10.2% from 15.4% in the prior quarter.
• Operating margin recovered dramatically from -27.0% in Q2 2024 to 15.4% in Q4 2025.
• ROIC expanded from -27.9% in Q2 2024 to 16.6% in Q4 2025, showing strong capital efficiency gains.
• ROE improved significantly from -20.7% in Q2 2024 to 13.3% in Q4 2025.
⚠ Operating margin dropped 520bp from 15.4% in Q4 2025 to 10.2% in Q1 2026.
⚠ ROIC fell to 10.4% in Q1 2026 from 16.6% in Q4 2025, breaking upward trend.
Get alerted when PEN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Penumbra Inc including:
Top Institutional Holders of PEN
BlackRock, Inc.
$1.4B4,330,456 shVANGUARD CAPITAL MANAGEMENT LLC
$556.4M1,694,488 shVANGUARD PORTFOLIO MANAGEMENT LLC
$543.3M1,654,477 shHBK INVESTMENTS L P
$536.6M1,634,261 shSTATE STREET CORP
$389.4M1,185,811 shMILLENNIUM MANAGEMENT LLC
$360.6M1,098,136 shBAILLIE GIFFORD & CO
$276.0M840,427 shGEODE CAPITAL MANAGEMENT, LLC
$261.3M795,448 shBALYASNY ASSET MANAGEMENT L.P.
$250.2M762,096 shGOLDMAN SACHS GROUP INC
$236.6M720,575 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $1.4B | 4,330,456 |
| VANGUARD CAPITAL MANAGEMENT LLC | $556.4M | 1,694,488 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $543.3M | 1,654,477 |
| HBK INVESTMENTS L P | $536.6M | 1,634,261 |
| STATE STREET CORP | $389.4M | 1,185,811 |
| MILLENNIUM MANAGEMENT LLC | $360.6M | 1,098,136 |
| BAILLIE GIFFORD & CO | $276.0M | 840,427 |
| GEODE CAPITAL MANAGEMENT, LLC | $261.3M | 795,448 |
| BALYASNY ASSET MANAGEMENT L.P. | $250.2M | 762,096 |
| GOLDMAN SACHS GROUP INC | $236.6M | 720,575 |
More Healthcare Companies
View all Healthcare →Put PEN on your watchlist
Track score changes the day Penumbra Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PEN a good stock to buy?
13F Pro's AI-powered analysis of Penumbra Inc (PEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PEN are available on the PEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PEN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Penumbra Inc's investment landscape.